Dipeptidyl peptidase-4 inhibitor (sitagliptin) improves insulin sensitivity and atherosclerosis-related biomarkers in patients with type 2 diabetes

被引：0
|
作者：
Yamane, T. [1 ]
Suzuki, Y. [1 ]
Iwai, R. [2 ]
Sakuma, Y. [2 ]
Yoshida, S. [1 ]
Hashimoto, N. [3 ]
机构：
[1] Asahi Gen Hosp, Chiba, Japan
[2] Asahi Gen Hosp, Clin Lab, Chiba, Japan
[3] Tokyo Womens Med Univ, Chiba, Japan
来源：
DIABETOLOGIA | 2012年 / 55卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
785
引用
收藏
页码：S323 / S323
页数：1
相关论文
共 50 条
  • [41] Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis
    Terawaki, Yuichi
    Nomiyama, Takashi
    Takahashi, Hiroyuki
    Tsutsumi, Yoko
    Murase, Kunitaka
    Nagaishi, Ryoko
    Tanabe, Makito
    Kudo, Tadachika
    Kobayashi, Kunihisa
    Yasuno, Tetsuhiko
    Nakashima, Hitoshi
    Yanase, Toshihiko
    DIABETOLOGY & METABOLIC SYNDROME, 2015, 7
  • [42] Cardiovascular outcomes of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes on insulin therapy
    Yen, Fu-Shun
    Chiang, Jen-Huai
    Pan, Chun-Wei
    Lin, Boniface J.
    Wei, James Cheng-Chung
    Hsu, Chih-Cheng
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2018, 140 : 279 - 287
  • [43] Efficacy of dipeptidyl peptidase-4 inhibitor linagliptin in patients with type 2 diabetes undergoing hemodialysis
    Yuichi Terawaki
    Takashi Nomiyama
    Hiroyuki Takahashi
    Yoko Tsutsumi
    Kunitaka Murase
    Ryoko Nagaishi
    Makito Tanabe
    Tadachika Kudo
    Kunihisa Kobayashi
    Tetsuhiko Yasuno
    Hitoshi Nakashima
    Toshihiko Yanase
    Diabetology & Metabolic Syndrome, 7
  • [44] Comparison of trough dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes treated with saxagliptin, sitagliptin, and vildagliptin
    Katzeff, H. L.
    Tatosian, D. A.
    Guo, Y.
    Schaeffer, A. K.
    Gaibu, N.
    Popa, S.
    Langdon, R. B.
    Kauh, E.
    DIABETOLOGIA, 2013, 56 : S53 - S53
  • [45] EFFICACY AND SAFETY OF SAXAGLIPTIN, DIPEPTIDYL PEPTIDASE-4 INHIBITOR, IN HEMODIALYSIS PATIENTS WITH TYPE 2 DIABETES
    Abe, M.
    Otsuki, T.
    Maruyama, N.
    Oikawa, O.
    Okada, K.
    NEPHROLOGY, 2016, 21 : 65 - 65
  • [46] Dipeptidyl peptidase-4 inhibitor treatment could decreaseKlebsiella pneumoniaepneumonia in patients with type 2 diabetes
    Chen, Hsin-Hung
    Chen, Ching-Chu
    Ho, Chun-Wei
    Hsieh, Ming-Chia
    Hsu, Sheng-Pang
    Lin, Cheng-Li
    Kao, Chia-Hung
    POSTGRADUATE MEDICINE, 2020, 132 (08) : 714 - 719
  • [47] DIPEPTIDYL PEPTIDASE-4 AND RISK OF PSORIASIS IN PATIENTS WITH TYPE 2 DIABETES
    Chen, W. S.
    Chang, Y. S.
    Tsai, C. Y.
    Chang, C. C.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1246 - 1247
  • [48] Sitagliptin: A dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes
    Miller, Shannon A.
    St. Onge, Erin L.
    ANNALS OF PHARMACOTHERAPY, 2006, 40 (7-8) : 1336 - 1343
  • [49] Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor, Improves Early-Phase Insulin Secretion in Drug-Naïve Patients with Type 2 Diabetes
    Ito R.
    Fukui T.
    Hayashi T.
    Osamura A.
    Ohara M.
    Hara N.
    Higuchi A.
    Yamamoto T.
    Hirano T.
    Drugs in R&D, 2015, 15 (3) : 245 - 251
  • [50] The effect of the dipeptidyl peptidase-4 inhibitor sitagliptin on gentamicin nephrotoxicity in mice
    Al Suleimani, Yousuf M.
    Abdelrahman, Aly M.
    Karaca, Turan
    Manoj, Priyadarsini
    Ashique, Mohammed
    Nemmar, Abderrahim
    Ali, Badreldin H.
    BIOMEDICINE & PHARMACOTHERAPY, 2018, 97 : 1102 - 1108
12345